九强生物
(300406)
| 流通市值：47.91亿 | | | 总市值：66.19亿 |
| 流通股本：4.24亿 | | | 总股本：5.86亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 334,810,688.09 | 1,355,507,324.47 | 1,011,713,943.43 | 668,335,957.13 |
| 营业收入 | 334,810,688.09 | 1,355,507,324.47 | 1,011,713,943.43 | 668,335,957.13 |
| 二、营业总成本 | 217,562,849.44 | 929,773,807.64 | 694,610,808.39 | 461,501,647.18 |
| 营业成本 | 60,471,472.54 | 279,921,068.94 | 203,746,803.43 | 136,402,199.32 |
| 税金及附加 | 5,334,191.44 | 18,520,752.54 | 14,509,560.83 | 9,236,973.09 |
| 销售费用 | 70,780,689.37 | 271,336,755.67 | 218,409,053.51 | 148,144,549.11 |
| 管理费用 | 29,497,452.78 | 137,545,457.88 | 99,103,514.81 | 63,385,975.74 |
| 研发费用 | 40,550,434.48 | 181,731,734.42 | 127,796,938.26 | 84,329,001.8 |
| 财务费用 | 10,928,608.83 | 40,718,038.19 | 31,044,937.55 | 20,002,948.12 |
| 其中:利息费用 | 12,439,357.2 | 49,443,237.05 | 36,193,872.28 | 23,821,162.56 |
| 其中:利息收入 | 1,197,377.59 | 10,435,527.73 | 6,224,512.84 | 4,718,353.53 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 3,665,217.16 | 12,135,601.29 | -1,042,719.12 | -742,471.47 |
| 资产处置收益 | -77,063.71 | -2,872,916.43 | -1,899,845.88 | -749,603.05 |
| 资产减值损失(新) | 0 | -180,755,267.59 | - | - |
| 信用减值损失(新) | 0 | -26,585,394.26 | -11,786,351.34 | -11,802,212.65 |
| 其他收益 | 3,106,311.02 | 8,327,332.07 | 5,467,784.02 | 3,286,887.22 |
| 四、营业利润 | 123,942,303.12 | 235,982,871.91 | 307,842,002.72 | 196,826,910 |
| 加:营业外收入 | 46,413.88 | 1,941,614.63 | 227,304.75 | 209,790.57 |
| 减:营业外支出 | 4,378.53 | 1,672,347.72 | 1,108,599.82 | 652,438.42 |
| 五、利润总额 | 123,984,338.47 | 236,252,138.82 | 306,960,707.65 | 196,384,262.15 |
| 减:所得税费用 | 18,373,065.47 | 45,714,851.05 | 33,889,866.5 | 20,670,296.99 |
| 六、净利润 | 105,611,273 | 190,537,287.77 | 273,070,841.15 | 175,713,965.16 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 105,611,273 | 190,537,287.77 | 273,070,841.15 | 175,713,965.16 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 105,607,356.33 | 189,874,176.06 | 272,460,775.18 | 175,233,795.64 |
| 少数股东损益 | 3,916.67 | 663,111.71 | 610,065.97 | 480,169.52 |
| 扣除非经常损益后的净利润 | 102,997,864.98 | 186,068,047.05 | 270,182,341.66 | 173,456,836.36 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.18 | 0.32 | 0.46 | 0.3 |
| (二)稀释每股收益 | 0.18 | 0.32 | 0.46 | 0.3 |
| 八、其他综合收益 | -338,607.92 | -495,498.1 | -233,627.67 | -89,167.78 |
| 归属于母公司股东的其他综合收益 | -253,955.94 | -372,617.64 | -176,342.91 | -67,998 |
| 九、综合收益总额 | 105,272,665.08 | 190,041,789.67 | 272,837,213.48 | 175,624,797.38 |
| 归属于母公司股东的综合收益总额 | 105,353,400.39 | 189,501,558.42 | 272,284,432.27 | 175,165,797.64 |
| 归属于少数股东的综合收益总额 | -80,735.31 | 540,231.25 | 552,781.21 | 458,999.74 |
| 公告日期 | 2026-04-27 | 2026-04-27 | 2025-10-29 | 2025-08-27 |
| 审计意见(境内) | | 标准无保留意见 | | |